GlassScriptPhysician profile
Brian C Toy
NPI 1659639540
$17,933.16
in general payments reported to CMS, 2019-2025
17 companies · $3,549 in 2025
The $3,549 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,511 · 2020: $205 · 2021: $601 · 2022: $1,459 · 2023: $3,212 · 2024: $4,397 · 2025: $3,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,640 · Food and Beverage: $2,967 · Honoraria: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,640.00 |
| Food and Beverage | $2,967.00 |
| Honoraria | $2,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $3,798.83 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $3,432.24 | 2022-2025 | Eylea Hd, Eylea |
| Ani Pharmaceuticals, INC. | $2,584.87 | 2025 | Iluvien, Purified Cortrophin Gel |
| Eyepoint US, INC. | $2,513.21 | 2021-2024 | |
| Bausch & Lomb Americas INC. | $1,601.17 | 2022-2025 | Xipere, Vyzulta, Miebo |
| Alcon Vision LLC | $1,449.70 | 2019-2025 | Hydrus Microstent |
| Alimera Sciences, INC. | $1,089.77 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $411.36 | 2019-2024 | Eylea, Eylea Hd, Dupixent |
| Abbvie INC. | $407.68 | 2023-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $190.14 | 2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $124.99 | 2019 | |
| Dermavant Sciences, INC. | $120.35 | 2023-2024 | Vtama |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $49.53 | 2019 | |
| Sun Pharmaceutical Industries INC. | $38.56 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.77 | 2024 | Tremfya, Simponi Aria, Simponi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Toy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.